@article { author = {Ahmad Abad, Fatemeh Shiokhi and Amin, Ahmad and Rezai, Roya and Mofidi Astaneh, Maryam and Nakhaie Amrodi, Akram and Naderi, Nasim and Taghavi, Sepide}, title = {Comparison of Serum Prolactin Levels Between the Acute Phase of Heart Failure and After Guideline-Directed Medical Therapy}, journal = {Iranian Heart Journal}, volume = {18}, number = {1}, pages = {20-24}, year = {2017}, publisher = {Iranian Heart Association}, issn = {}, eissn = {}, doi = {}, abstract = {Background: Prolactin (PRL) has increasingly been recognized to play a stimulatory role ininflammatory response. Recently, studies have reported an increase in the PRL level amongpatients with chronic heart failure (HF); however, there are conflicting data about its role asa prognostic factor in these patients. We aimed to measure the PRL level in the acute phaseof HF and the post guideline-directed medical therapy (GDMT) of HF to clarify whetherPRL is an acute-phase reactant or more than an acute phase-reactant in patients with HF.Methods: The serum PRL level was assessed in 94 patients with HF in the acute phase of HFdecompensation and post-GDMT of HF. Serum N-terminal pro-brain natriuretic peptide,high-sensitive C-reactive protein, 6-minute walk test, erythrocyte sedimentation rate, CRP,blood urea nitrogen, creatinine, serum sodium, and white blood cell count were alsomeasured. Our secondary end points were mortality, transplantation, and hospitalization dueto acute HF. All the patients were followed up for 6 months.Results: The mean serum PRL level in the acute phase was 31.3 ng/mL, which was significantlyhigher than the normal reference values (4.04–15 ng/mL) (P < 0.001). The mean serum PRLlevel before discharge was 34.84 ng/mL, which was significantly higher than the normalreference values and similar to the acute phase values. The mean PRL level in the patientswith dilated cardiomyopathy was 33.61 ng/mL in the acute phase and 43.15 ng/mL after theGDMT of HF. The mean PRL level in the patients without dilated cardiomyopathy was33.42 ng/mL in the acute phase and 29.92 ng/mL before discharge. The mean PRL level inthe patients with re-admission was higher (27.7 ng/mL in the acute phase and 29.7 ng/mLbefore discharge in the patients with no re-admission and 37.4 ng/mL in the acute phase and42.5 ng/mL before discharge in the patients with re-admission).Conclusions: In 57% of the patients, the mean level of PRL increased after treatment. The levelremained unchanged in 3.5% of the patients and had a drop in 39.2%. Our findings suggestthat PRL may be more than an acute-phase reactant alone. Larger studies are needed tofurther elucidate the role of PRL in patients with HF. Research regarding the treatment ofpatients suffering from HF with high levels of PRL post-GDMT of HF with bromocriptinemay have consequences like those in peripartum cardiomyopathy.}, keywords = {Hyperprolactinemia,Cardiomyopathy,Peripartum}, url = {http://journal.iha.org.ir/article_82754.html}, eprint = {http://journal.iha.org.ir/article_82754_e4cc9fb21ba6e851e5a1d320b9d5c815.pdf} }